Oncology Institute (TOI) Shares Outstanding (Weighted Average) (2019 - 2026)

Oncology Institute has reported Shares Outstanding (Weighted Average) for 8 years, with the latest figure at $101.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 32.04% year-over-year to $101.8 million; the trailing twelve-month figure through Mar 2026 stood at $101.8 million (up 32.04% YoY), and the FY2025 full-year result was $92.4 million, up 23.11% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $101.8 million, up from $89.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $101.8 million in Q1 2026, with the low at $72.2 million in Q3 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $77.9 million across 5 years, with a median of $74.2 million in 2023.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) gained 0.27% — and 2026, when it soared 32.04%.
• Oncology Institute's Shares Outstanding (Weighted Average) stood at $72.8 million in 2022, then advanced by 1.31% to $73.7 million in 2023, then advanced by 1.76% to $75.0 million in 2024, then rose by 19.04% to $89.3 million in 2025, then increased by 13.96% to $101.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $101.8 million (Q1 2026), $89.3 million (Q3 2025), and $93.2 million (Q2 2025), per Business Quant data.